Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Phase 4

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]

First Posted Date: 2008-08-19

Last Posted Date: 2017-12-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 132

Registration Number: NCT00737464

Locations: 🇮🇳
Nizam's Institute of Medical Sciences; Nephrology, Hyderabad, India
🇮🇳
Wockhardt Hospital and Kidney Institute; Nephrology, Kolkata, India
🇮🇳
Meerut Kidney Hospital, Meerut, India

and more 14 locations

A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Methoxy polyethylene glycol-epoetin beta

First Posted Date: 2008-08-19

Last Posted Date: 2017-06-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 96

Registration Number: NCT00737477

Locations: 🇫🇷
Arauco; Arauco Tours Bretonneau, Tours, France
🇫🇷
Centre Hospitalier; Hemodialyse, Annonay, France
🇫🇷
Ch Notre Dame Misericorde; Hemodialyse, Ajaccio, France

and more 49 locations

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Phase 4

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]

First Posted Date: 2008-08-19

Last Posted Date: 2016-06-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 189

Registration Number: NCT00737711

A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: RO5083945

First Posted Date: 2008-07-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 102

Registration Number: NCT00721266

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2008-07-23

Last Posted Date: 2013-11-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 538

Registration Number: NCT00721123

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Disease-modifying anti-rheumatic drugs
Drug: Non-steroidal anti-inflammatory drugs
Drug: Oral corticosteroids

First Posted Date: 2008-07-23

Last Posted Date: 2014-09-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2067

Registration Number: NCT00720798

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Epoetin Beta
Drug: Methoxy Polyethylene Glycol-epoetin Beta
Drug: Darbepoetin Alfa

First Posted Date: 2008-07-18

Last Posted Date: 2021-09-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 421

Registration Number: NCT00717821

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Phase 3

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Cladribine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-07-18

Last Posted Date: 2018-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 128

Registration Number: NCT00718549

Locations: 🇧🇾
City Clinical Hospital #9, Minsk, Belarus
🇵🇱
Szpital Uniwersytecki W Krakowie; Klinika Hematologii, Krakow, Poland
🇵🇱
Medical University, Independent Public Clinical Hospital; Dept. of Hematology, SPSK, Bialystok, Poland

and more 3 locations

A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: erlotinib [Tarceva]
Drug: erythromycin [Eritex]
Drug: Fisiogel
Drug: fusidic acid [Verutex]

First Posted Date: 2008-07-18

Last Posted Date: 2015-01-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 201

Registration Number: NCT00718315

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: exenatide
Drug: taspoglutide

First Posted Date: 2008-07-17

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1189

Registration Number: NCT00717457

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy